AORT

Artivion, Inc. is a medical device company focused on developing solutions that address cardiac and vascular surgeons’ challenges in treating patients with aortic diseases. The Company is engaged in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. It has four major product families: aortic stent grafts, surgical sealants, On-X mechanical heart valves and related surgical products, and implantable cardiac and vascular human tissues. Its Medical Devices segment includes sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. Its Preservation Services segment includes services for the preservation of cardiac and vascular implantable human tissues. Aortic stent grafts include aortic arch stent grafts, abdominal stent grafts, and synthetic vascular grafts. Surgical sealants include its BioGlue Surgical Adhesive products.

Wall Street analysts forecast AORT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AORT is 51.71 USD with a low forecast of 40.00 USD and a high forecast of 58.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Artivion Inc revenue for the last quarter amounts to 113.39M USD, increased 18.39 % YoY.

Artivion Inc. EPS for the last quarter amounts to 0.13 USD, decreased -360.00 % YoY.

Artivion Inc (AORT) has 1600 emplpoyees as of December 16 2025.

Today AORT has the market capitalization of 2.15B USD.